Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. It is estimated that
25% of the world's population are infected with Mycobacterium tuberculosis, with a 5–10 …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

Tuberculosis (TB) is the leading cause of death from a single infectious agent, requiring at
least 6 months of multidrug treatment to achieve cure. However, the lack of reliable data on …

Rifampicin was discovered in 1965 and remains one of the most important drugs in
tuberculosis treatment that is valued for its sterilizing activity and ability to shorten treatment …

Background Shorter but effective tuberculosis treatment regimens would be of value to the
tuberculosis treatment community. High-dose rifampicin has been associated with more …

Tuberculous meningitis (TBM) is a devastating form of tuberculosis (TB), and key TB
antimicrobials, including rifampin, have restricted brain penetration. A lack of reliable data …

Guidelines on the treatment of tuberculosis (TB) have essentially remained the same for the
past 35 years, but are now starting to change. Ongoing clinical trials will hopefully transform …

Ocular infection caused by Mycobacterium tuberculosis affected an estimated 0.1− 0.2
million people in the year 2018 worldwide and may result in irreversible loss of vision if not …

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …

Background Recent evidence suggests that higher rifampicin doses may improve
tuberculosis (TB) treatment outcome. Methods In this observational cohort study we …